Abstract
Raynaud’s phenomenon (RP) is commonly observed in fingers and toes of patients with connective tissue diseases (CTDs). However, existing vasodilators have very limited efficacy. In this study, phosphodiesterase type 5 inhibitors (PDE-5Is) were administered to evaluate efficacy on RP. Three patients with mixed connective tissue disease and three patients with systemic sclerosis having RP were enrolled. Oral sildenafil, vardenafil, or tadalafil was administered. The fingertip temperature was measured by thermography before and 120 min after administration. To evaluate longer effects, vardenafil was administered daily for 12 weeks; the fingertip temperature was measured by thermography before and 12 weeks after administration. As compared with the pre-administration of sildenafil, vardenafil, and tadalafil, the mean fingertip temperature increased by 2.17, 3.47, and 3.59 °C, respectively, in 120 min. In the 12-week trial with vardenafil in 3 patients, the mean fingertip temperature increased by 3.04, 7.96, and 3.32 °C from baseline in each patient. PDE-5Is significantly increased fingertip temperature within 120 min, and the effect of vardenafil lasted for 12 weeks under daily use. PDE-5Is were safe and would be an effective treatment for RP with CTDs.
References
Wollersheim H, VanZwieten PA (1993) Treatment of Raynaud’s phenomenon. Eur Heart J 14(2):147–149
Smith CD, McKendry RJ (1982) Controlled trial of nifedipine in the treatment of Raynaud’s phenomenon. Lancet 11(8311):1299–1301
Langevitz P, Buskila D, Lee P, Urowitz MB (1989) Treatment of refractory ischemic skin ulcers in patients with Raynaud’s phenomenon with PGE1 infusions. J Rheumatol 16(11):1433–1435
Kirby JD, Lima DR, Dowd PM, Kilfeather S, Turner P (1980) Prostacyclin increases cyclic-nucleotide responsiveness of lymphocytes from patients with systemic sclerosis. Lancet 30(8192):453–454
Dinerman JL, Lowenstein CJ, Snyder SH (1993) Molecular mechanisms of nitric oxide regulation. Potential relevance to cardiovascular disease. Circ Res 73(2):217–222
Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75(4):725–748
Abrams D, Schulze-Neick I, Magee AG (2000) Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 84:E4
Sanchez LS, de la Monte SM, Filippov G, Jones RC, Zapol WM, Bloch KD (1998) Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. Pediatr Res 43(2):163–168
Padma-Nathan H, Christ G, Adaikan G, Becher E, Brock G, Carrier S, Carson C, Corbin J, Francis S, DeBusk R, Eardley I, Hedlund H, Hutter A, Jackson G, Kloner R, Lin CS, McVary K, McCullough A, Nehra A, Porst H, Schulman C, Seftel A, Sharlip I, Stief C, Teloken C (2004) Pharmacotherapy for erectile dysfunction. J Sex Med 1(2):128–140
Kamata Y, Nara H, Sato H, Masuyama J-I, Minota S (2005) Effect of steroid pulse therapy on mixed connective tissue disease with pulmonary arterial hypertension. Ann Rheum Dis 64(8):1236–1237
Fries R, Shariat K, von Wilmowsky H, Böhm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112(19):2980–2985
Roustit M, Hellmann M, Cracowski C, Blaise S, Cracowski JL (2012) Sildenafil increases digital skin blood flow during all phases of local cooling in primary Raynaud’s phenomenon. Clin Pharmacol Ther 91(5):813–819
Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL (2013) Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 72(10):1696–1699
Wright PJ (2006) Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract 60(8):967–975
Conflict of interest
None.
Ethical standard
This study was approved by the ethics committee of the Jichi Medical University, Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kamata, Y., Minota, S. Effects of phosphodiesterase type 5 inhibitors on Raynaud’s phenomenon. Rheumatol Int 34, 1623–1626 (2014). https://doi.org/10.1007/s00296-014-3025-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-014-3025-z